Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707217 | 0.98 | CYP1A2 (0.52) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL13323625 | 0.92 | CYP1A2 (0.53) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL14180061 | 0.86 | DGKA (0.47) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL14180017 | 0.86 | DGKA (0.47) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL3882499 | 0.86 | DGKA (0.61) | DGKAMAPTLMNAALDH1A1TSHR | |
| SCHEMBL14180018 | 0.86 | DGKA (0.47) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL14180021 | 0.86 | DGKA (0.47) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL14180019 | 0.86 | DGKA (0.47) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL3823424 | 0.84 | CYP1A2 (0.47) | DGKACYP1A2MAPTLMNAALDH1A1 | |
| SCHEMBL17148353 | 0.84 | DGKA (0.53) | DGKAMAPTLMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | DGKA 4084/4885CYP1A2 1120/4885MAPT 4635/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | DGKA 4384/4885CYP1A2 875/4885MAPT 4426/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | DGKA 4384/4885CYP1A2 875/4885MAPT 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.